OraSure Secures FDA Clearance for At-Home Urine Collection Kit for STI Testing with Roche Systems
OSUR sits 98% above its 52-week low of $2.08 on light trading volume (0.4× avg).
Summary
OraSure Technologies announced FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, enabling convenient at-home self-collection for STI testing with Roche's molecular diagnostic systems. This clearance provides a new growth avenue for the company amidst recent revenue declines.
Key Events · Product Development and Regulatory · OSUR
-
FDA Clearance Received
OraSure Technologies received U.S. FDA clearance for its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc.
-
Enhanced Accessibility for STI Testing
The kit supports at-home self-collection of first-void urine, enabling convenient at-home sample collection for both male and female patients for STI testing.
-
Integration with Roche Systems
The cleared kit is for use with Roche Molecular Systems, Inc. tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems.
-
Strategic Product Advancement
This clearance provides a new product offering that could help counter recent revenue declines and losses reported by the company, supporting future growth.
Analysis · OSUR · Industrial Applications And Services
This FDA clearance is a significant positive development for OraSure Technologies, especially given its recent financial performance marked by revenue declines and widened losses. The Colli-Pee™•Dx kit, designed for at-home self-collection of urine for STI testing, expands market accessibility and convenience, potentially boosting testing volumes. Its compatibility with Roche's established molecular diagnostic systems further enhances its market potential. While the news was previously reported by GlobeNewswire today, this 8-K serves as the official regulatory confirmation of a key product advancement that could contribute to future revenue growth.
At the time of this filing, OSUR was trading at $4.11 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $283M. The 52-week trading range was $2.08 to $4.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.